Disease-free survival (DFS) was determined from day of transplantation (day 0) to date of relapse of disease.
Event-free survival was determined from the first day of therapy to relapse, death from any cause, or last visit.
Distance disease-free survival (DDFS) was calculated for the M0 group from the day of diagnosis until relapse.
The usefulness of our approach is its capacity to reliably predict a 29 day (or a 63 day interval estimated by interpolation) interval of relapse detection from crossing the WT1 ratio of 50, a relatively low ratio.
"Suddenly, she only had weeks to live". Image caption: Spencer Grace on her last day of chemotherapy before her relapse.
Moreover, relapses that occur after day 63 may deliver similar rates of relapse, regardless of the excretion rate of the blood schizontocide.
Demographic, epidemiological and clinical data, co-morbid conditions, antibiotics and proton pump inhibitors (PPI) consumption within the three months prior to diagnosis of CDI, as well as treatment, rate of relapse and 30 day crude and attributable mortality, were registered and analysed in a Microsoft EXCEL™ database.
Consequently, the interval between the day of peritonectomy and HIPEC and the diagnosis of relapse was defined as the relapse-free period, given in days (time to relapse, TTR).
Some patients with positive MRD at day 33 (one of the most powerful predictors of relapse) remained in CCR while others with negative MRD relapsed.
Relapse-free survival time was defined as the period from the day of surgery to the day of final confirmation of a relapse-free status or to the first confirmation of relapse.
Steroid dosage at the point of relapse varied from 30 mg of prednisolone per day to hydrocortisone replacement therapy.
